Alan McCormick is a founding Partner of the purpose-driven investment firm Legatum. He serves on the Board of Directors for the END Fund, and is Chairman for the Luminos Fund, the Legatum Institute and the Freedom Fund. Mr McCormick is also a supporter of many other causes that promote greater freedom and prosperity around the world.
Legatum’s mission is to generate and allocate the capital and ideas that help people live more prosperous lives. To achieve this mission, Legatum focuses on three core pillars: 1) Investing proprietary capital, mainly in public markets, with a focus on long-term value creation; 2) originating, incubating and scaling ground-breaking philanthropic initiatives that tackle the biggest challenges of our generation; and 3) generating ideas which help society progress along the pathways from poverty to prosperity.
Over the last decade, Mr McCormick and his Partners have founded several philanthropic funds, which include the END Fund, the largest private investment vehicle for eliminating Neglected Tropical Diseases (NTDs). Legatum started tackling NTDs in 2006, in Rwanda and Burundi, by trialling the first mass drug administration, which ultimately treated over 9.7 million people in four years. Seeing that NTDs affected over one billion of the world’s population, Legatum established the END Fund in 2012 as an independent vehicle to bring together private donors to accomplish one big goal: to see an end to the most prevalent NTDs once and for all.
Mr McCormick has been with Legatum since its founding in 2006. He was formerly part of Legatum’s predecessor, Sovereign Asset Management, and a member of its special situations team. Prior to that he worked for JP Morgan.